DRW Securities’s Biogen BIIB Stock Holding History

DRW Securities’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000	Closed	-$240K	–	67
2017 Q2	$240K	Buy	+1,000	New	+$264K	0.04%	54

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DRW Securities's BIIB Position: Q2 2026 in Review

DRW Securities sold out of Biogen (BIIB) in Q2 2026, closing a stake of 1,335 shares — an estimated $244K sold.

DRW Securities first reported a position in BIIB in Q2 2014 and held it in 11 quarters. The position peaked at $9.99M in Q2 2014. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

DRW Securities reported no remaining Biogen position as of Q2 2026 after selling out during the quarter.
DRW Securities sold 1,335 Biogen shares in Q2 2026, an estimated $244K.
DRW Securities first reported a position in Biogen in Q2 2014 and held it in 11 quarters.
DRW Securities's Biogen position peaked at $9.99M in Q2 2014.
1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.